Corvus Pharmaceuticals, Inc. (CRVS) — 8-K Filings

8-K Filings (19)

• 8-K Filing — Nov 4, 2025
• Corvus Pharmaceuticals Reports Leadership and Compensation Changes — Oct 2, 2025 Risk: medium
  Corvus Pharmaceuticals, Inc. filed an 8-K on October 2, 2025, reporting changes in its board of directors and certain officers, along with updates to compensato
• Corvus Pharmaceuticals Files 8-K on Financials — Aug 7, 2025 Risk: low
  Corvus Pharmaceuticals, Inc. filed an 8-K on August 7, 2025, reporting on its results of operations and financial condition, and including financial statements
• Corvus Pharmaceuticals Files 8-K on Shareholder Vote Matters — Jun 13, 2025 Risk: low
  Corvus Pharmaceuticals, Inc. filed an 8-K on June 13, 2025, reporting on matters submitted to a vote of security holders as of June 12, 2025. The filing details
• Corvus Pharmaceuticals Files 8-K — Jun 4, 2025 Risk: low
  Corvus Pharmaceuticals, Inc. filed an 8-K on June 4, 2025, reporting on events including a Regulation FD Disclosure, Other Events, and Financial Statements and
• Corvus Pharmaceuticals Files 8-K — May 8, 2025 Risk: low
  Corvus Pharmaceuticals, Inc. filed an 8-K on May 8, 2025, reporting on results of operations, financial condition, and other events. The filing includes financi
• Corvus Pharma Announces Executive and Board Changes — Apr 9, 2025 Risk: medium
  Corvus Pharmaceuticals, Inc. announced on April 8, 2025, changes in its executive and director roles. The company appointed Dr. Richard A. Miller as Chief Medic
• Corvus Pharmaceuticals Files 8-K on Financials — Mar 25, 2025 Risk: low
  Corvus Pharmaceuticals, Inc. filed an 8-K on March 25, 2025, reporting on its results of operations and financial condition. The filing includes financial state
• Corvus Pharmaceuticals Files 8-K — Jan 13, 2025 Risk: low
  On January 13, 2025, Corvus Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, and other events, withou
• Corvus Pharmaceuticals Files 8-K — Dec 18, 2024 Risk: low
  Corvus Pharmaceuticals, Inc. filed an 8-K on December 18, 2024, reporting on various events. The filing includes information related to Regulation FD Disclosure
• Corvus Pharmaceuticals Files 8-K — Nov 12, 2024 Risk: low
  Corvus Pharmaceuticals, Inc. filed an 8-K on November 12, 2024, to report on its results of operations and financial condition, as well as to file financial sta
• Corvus Pharmaceuticals Files 8-K — Oct 23, 2024 Risk: low
  Corvus Pharmaceuticals, Inc. filed an 8-K on October 23, 2024, reporting an entry into a material definitive agreement and financial statements. The filing does
• Corvus Pharmaceuticals Files 8-K — Aug 6, 2024 Risk: low
  Corvus Pharmaceuticals, Inc. filed an 8-K on August 6, 2024, to report on its results of operations and financial condition, as well as to file financial statem
• Corvus Pharmaceuticals Files 8-K on Shareholder Vote Matters — Jun 14, 2024 Risk: low
  Corvus Pharmaceuticals, Inc. filed an 8-K on June 14, 2024, reporting on matters submitted to a vote of security holders as of June 13, 2024. The filing does no
• Corvus Pharmaceuticals Enters Material Definitive Agreement — May 6, 2024 Risk: medium
  Corvus Pharmaceuticals, Inc. announced on May 1, 2024, that it entered into a material definitive agreement. The filing also includes financial statements and e
• Corvus Pharmaceuticals Files 8-K on Financials — May 6, 2024 Risk: low
  Corvus Pharmaceuticals, Inc. filed an 8-K on May 6, 2024, reporting on its results of operations and financial condition. The filing includes financial statemen
• Corvus Pharmaceuticals Files 8-K — May 1, 2024 Risk: low
  Corvus Pharmaceuticals, Inc. filed an 8-K on May 1, 2024, to report other events and financial statements. The filing does not contain specific details about ne
• Corvus Pharmaceuticals Files 8-K on Financials — Mar 19, 2024 Risk: low
  Corvus Pharmaceuticals, Inc. filed an 8-K on March 19, 2024, reporting on its results of operations and financial condition. The filing includes financial state
• Corvus Pharma Reports Executive/Director Changes, Comp Arrangements — Jan 23, 2024
  Corvus Pharmaceuticals, Inc. filed an 8-K on January 23, 2024, to report a 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Ce

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX